Page last updated: 2024-11-05

1,8-octanedithiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,8-Octanedithiol is a bifunctional organic compound containing two thiol groups at the ends of an eight-carbon chain. It is a colorless liquid with a strong odor. It is commonly used as a building block in the synthesis of various organic compounds, including polymers, pharmaceuticals, and materials. The compound is synthesized through a multi-step process that involves the reaction of 1,8-octanediol with phosphorus pentasulfide. 1,8-octanedithiol has applications in various fields, including: as a cross-linking agent for polymers, enhancing their properties; as a precursor in the synthesis of various sulfur-containing compounds, including thiols, sulfides, and disulfides; as a ligand in coordination chemistry, forming complexes with transition metals; as a building block for the construction of self-assembled monolayers (SAMs) on gold surfaces, which are widely used in nanotechnology and electronics. The study of 1,8-octanedithiol is important due to its versatile applications in different scientific and technological areas. Researchers are interested in exploring its potential in various fields, including materials science, biomedicine, and catalysis. This interest stems from its unique properties, including its bifunctional nature, reactivity with metals, and ability to form ordered structures.'

Cross-References

ID SourceID
PubMed CID14493
CHEMBL ID3188161
CHEBI ID172319
SCHEMBL ID63238
MeSH IDM0505698

Synonyms (38)

Synonym
1191-62-4
CHEBI:172319
octamethylene dimercaptan
fema no. 3514
1,8-dimercaptooctane
einecs 214-738-8
octane-1,8-dithiol
1,8-octamethylenedithiol
brn 1735431
1,8-octanedithiol
1,8-octanedithiol, >=97%
1,8-octanedithiol, >=97%, fg
A804209
kh3w3161hs ,
unii-kh3w3161hs
4-01-00-02592 (beilstein handbook reference)
dtxsid8047474 ,
tox21_303621
cas-1191-62-4
dtxcid6027474
NCGC00256698-01
O0374
FT-0607060
AKOS015897631
octanedithiol, 1,8-
1,8-octanedithiol [fhfi]
SCHEMBL63238
PGTWZHXOSWQKCY-UHFFFAOYSA-N
CHEMBL3188161
J-004076
mfcd00003574
nanothinks(tm) thio8
fema 3514
BCP08455
Q27282247
D91866
AS-56856
?1,8-octanedithiol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkanethiolAn alkanethiol is a compound in which a sulfanyl group, -SH, is attached to an alkyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency0.01930.000221.22318,912.5098AID743042
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.86350.003041.611522,387.1992AID1159552
activating transcription factor 6Homo sapiens (human)Potency25.37790.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
histone deacetylase 9 isoform 3Homo sapiens (human)Potency68.58960.037617.082361.1927AID1259364
heat shock protein beta-1Homo sapiens (human)Potency61.64480.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency46.86730.000627.21521,122.0200AID743202; AID743219
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency76.95880.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency76.95880.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (38.46)29.6817
2010's8 (61.54)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.58 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index35.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]